v3.25.4
STATEMENTS OF CHANGES IN MEMBERS' DEFICIT - Liminatus Pharma, LLC - USD ($)
$ in Thousands
Member Units
Class A Member Units
Member Units
Class B Member Units
Additional Paid-in Capital
Accumulated Deficit
Class A Member Units
Class B Member Units
Total
Beginning balance at Dec. 31, 2022 $ 4,000 $ 167 $ 5,158 $ (20,135)     $ (10,810)
Beginning balance (In units) at Dec. 31, 2022 57,000,000 16,666,666          
Increase (Decrease) in Partners' Capital [Roll Forward]              
Cancellation of member units related to Metavagen license termination $ (239)   239        
Cancellation of member units related to Metavagen license termination (In units) (40,000,000)            
Issuance of Class A member units in exchange for CD-47 License Agreement $ 786   (786)        
Issuance of Class A member units in exchange for CD-47 License Agreement (In units) 78,555,554            
Net loss       (4,984) $ (2,442) $ (2,542) (4,984)
Ending balance at Dec. 31, 2023 $ 4,547 $ 167 4,611 (25,119)     (15,794)
Ending balance (In units) at Dec. 31, 2023 95,555,554 16,666,666          
Increase (Decrease) in Partners' Capital [Roll Forward]              
Net loss $ 0 $ 0 0 (3,546) $ (1,738) $ (1,808) (3,546)
Ending balance at Dec. 31, 2024 $ 4,547 $ 167 $ 4,611 $ (28,665)     $ (19,340)
Ending balance (In units) at Dec. 31, 2024 95,555,554 16,666,666